CONTRAFECT CORP
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CFRXQ and buy or sell other stocks, ETFs, and their options commission-free!About CFRXQ
ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides.
CEOMichael Messinger, CPA
CEOMichael Messinger, CPA
Employees23
Employees23
HeadquartersYonkers, New York
HeadquartersYonkers, New York
Founded2008
Founded2008
Employees23
Employees23
CFRXQ Key Statistics
Market cap1.07K
Market cap1.07K
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume44.00
Average volume44.00
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$0.0005
52 Week high$0.0005
52 Week low$0.00
52 Week low$0.00
Stock Snapshot
As of today, CONTRAFECT CORP(CFRXQ) shares are valued at $0.00. The company's market cap stands at 1.07K.
On 2026-03-02, CONTRAFECT CORP(CFRXQ) stock opened at —, reached a high of —, and a low of —.
The CONTRAFECT CORP(CFRXQ)'s current trading volume is 0, compared to an average daily volume of 44.
In the last year, CONTRAFECT CORP(CFRXQ) shares hit a 52-week high of $0.00 and a 52-week low of $0.00.
In the last year, CONTRAFECT CORP(CFRXQ) shares hit a 52-week high of $0.00 and a 52-week low of $0.00.
People also own
Based on the portfolios of people who own CFRXQ. This list is generated using Robinhood data, and it’s not a recommendation.